| Recruiting | Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer NCT06617923 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT06342986 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Terminated | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary NCT05538624 | Avenge Bio, Inc | Phase 1 / Phase 2 |
| Recruiting | A Study of XMT-1660 in Participants With Solid Tumors NCT05377996 | Mersana Therapeutics | Phase 1 |
| Completed | FT516 and IL2 With Enoblituzumab for Ovarian Cancer NCT04630769 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian NCT01402271 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 1 / Phase 2 |
| Completed | Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or NCT01656044 | Wake Forest University Health Sciences | N/A |
| Completed | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epitheli NCT00872989 | SWOG Cancer Research Network | Phase 2 |
| Completed | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallop NCT00993616 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Prim NCT00903396 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Unknown | Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With NCT01100372 | Medical University Innsbruck | Phase 2 |
| Completed | Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix NCT01580410 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian E NCT00569673 | Gynecologic Oncology Group | Phase 2 |
| Completed | Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surger NCT00769405 | UNICANCER | Phase 3 |
| Terminated | AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or NCT00574951 | Gynecologic Oncology Group | Phase 2 |
| Completed | Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Per NCT00562640 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly D NCT00838656 | Warwick Medical School | Phase 2 |
| Completed | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or NCT00093496 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in NCT00522301 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer NCT00766142 | Institut Bergonié | Phase 2 |
| Completed | Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fall NCT00459290 | Gynecologic Oncology Group | Phase 2 |
| Completed | Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer D NCT00458809 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary NCT00429793 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal NCT00407758 | Gynecologic Oncology Group | Phase 2 |
| Completed | Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Sm NCT00398138 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, NCT00303888 | Yale University | Phase 1 |
| Terminated | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or NCT00373217 | Craig L Slingluff, Jr | Phase 2 |
| Completed | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallop NCT00334893 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epith NCT00483782 | Medical Research Council | Phase 3 |
| Unknown | Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube NCT00897039 | Southeastern Gynecologic Oncology | — |
| Unknown | Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Brea NCT00601406 | The Christie NHS Foundation Trust | N/A |
| Completed | Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity C NCT00132067 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, P NCT00263822 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or NCT00081276 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer NCT00113373 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube NCT00126542 | National Cancer Institute (NCI) | Phase 2 |
| Completed | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometria NCT00107445 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer NCT00114166 | Gynecologic Oncology Group | Phase 2 |
| Completed | CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fal NCT00096239 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity C NCT00138242 | Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center | Phase 2 |
| Terminated | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer NCT00091195 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallop NCT00091377 | MEI Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer NCT00087087 | Gynecologic Oncology Group | Phase 2 |
| Completed | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulkin NCT00079430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer NCT00091273 | University of Virginia | Phase 1 |
| Completed | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal NCT00086892 | Gynecologic Oncology Group | Phase 2 |
| Completed | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in T NCT00085358 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, R NCT00408590 | Mayo Clinic | Phase 1 |
| Terminated | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epitheli NCT00084448 | Gynecologic Oncology Group | Phase 2 |
| Unknown | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Pe NCT00305838 | Mount Vernon Cancer Centre at Mount Vernon Hospital | Phase 2 |
| Completed | Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT00098878 | NHS Greater Glasgow and Clyde | Phase 3 |
| Completed | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epitheli NCT00072267 | University Health Network, Toronto | Phase 2 |
| Completed | Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fall NCT00075712 | Royal College of Obstetricians and Gynecologists | Phase 2 / Phase 3 |
| Completed | Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors NCT00066651 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer NCT00066729 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer NCT00053365 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tub NCT00053833 | SWOG Cancer Research Network | Phase 2 |
| Completed | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, o NCT00041080 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritonea NCT00058435 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Gefitinib in Treating Patients With Cervical Cancer NCT00049556 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded t NCT00025155 | National Cancer Institute (NCI) | Phase 2 |
| Completed | UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or NCT00045175 | University Health Network, Toronto | Phase 1 |
| Completed | Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal C NCT00041041 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Prim NCT00039585 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer NCT00055614 | Beth Israel Deaconess Medical Center | Phase 1 |
| Completed | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Can NCT00036751 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal NCT00022659 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal C NCT00023712 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peri NCT00028912 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for NCT00028782 | National Cancer Institute (NCI) | N/A |
| Completed | Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Ca NCT00023699 | Gynecologic Oncology Group | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer NCT00031954 | AGO Study Group | Phase 2 |
| Terminated | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer NCT00023907 | Gynecologic Oncology Group | Phase 2 |
| Completed | Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer NCT00016289 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Pe NCT00020696 | Gynecologic Oncology Group | Phase 2 |
| Completed | TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Periton NCT00022347 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, NCT00014690 | AstraZeneca | Phase 2 |
| Completed | Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary P NCT00021034 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer NCT00006812 | Gynecologic Oncology Group | Phase 2 |
| Completed | CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal NCT00017017 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer Th NCT00006028 | Gynecologic Oncology Group | Phase 2 |
| Unknown | Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Pe NCT00017303 | Cytran | Phase 2 |
| Completed | Immunotoxin Therapy in Treating Patients With Advanced Cancer NCT00006981 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallop NCT00006942 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum NCT00012090 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, o NCT00005025 | John Stoddard Cancer Center at Iowa Methodist Medical Center | Phase 2 |
| Unknown | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian E NCT00045461 | Ludwig-Maximilians - University of Munich | Phase 2 / Phase 3 |
| Completed | Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer NCT00005046 | Gynecologic Oncology Group | Phase 1 |
| Terminated | Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer NCT00005029 | Gynecologic Oncology Group | Phase 2 |
| Completed | Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal NCT00005836 | Gynecologic Oncology Group | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Periton NCT00005026 | Gynecologic Oncology Group | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer NCT00006041 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer NCT00003967 | Gynecologic Oncology Group | Phase 1 |
| Completed | Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage NCT00004934 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Phase 3 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peri NCT00004060 | Daiichi Sankyo | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors NCT00004082 | Beth Israel Deaconess Medical Center | Phase 1 |
| Terminated | Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorecta NCT00005944 | UNICANCER | Phase 2 |
| Completed | SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) NCT00002960 | Merck Sharp & Dohme LLC | Phase 1 |
| Withdrawn | ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous T NCT00005645 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer NCT00003385 | Gynecologic Oncology Group | Phase 1 |
| Terminated | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovar NCT00003880 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Completed | Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cance NCT00003523 | Gynecologic Oncology Group | Phase 2 |
| Completed | Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT00004012 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cance NCT00003624 | Gynecologic Oncology Group | Phase 2 |
| Unknown | Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission NCT00004115 | Jonsson Comprehensive Cancer Center | Phase 3 |
| Unknown | Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer NCT00004064 | AltaRex | Phase 2 |
| Completed | Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer NCT00003998 | University of Glasgow | Phase 3 |
| Completed | Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or P NCT00003670 | Eli Lilly and Company | Phase 2 |
| Completed | Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer NCT00019552 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tu NCT00003636 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Terminated | Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Prima NCT00003378 | Gynecologic Oncology Group | Phase 1 |
| Terminated | Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer NCT00004037 | Gynecologic Oncology Group | Phase 2 |
| Unknown | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary NCT00003560 | Herbert Irving Comprehensive Cancer Center | Phase 2 |
| Terminated | Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, NCT00003380 | Gynecologic Oncology Group | Phase 1 |
| Terminated | Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recur NCT00003382 | Gynecologic Oncology Group | Phase 1 |
| Completed | Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or NCT00019461 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epit NCT00003634 | AltaRex | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer NCT00003322 | Gynecologic Oncology Group | Phase 3 |
| Completed | Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube NCT00003358 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer NCT00003345 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Pacli NCT00003160 | Theradex | Phase 2 |
| Unknown | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persi NCT00003064 | Herbert Irving Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian NCT00003136 | University of Chicago | Phase 1 / Phase 2 |
| Completed | Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Re NCT00002895 | Medical Research Council | Phase 3 |
| Completed | Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian NCT00002734 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal NCT00002717 | Gynecologic Oncology Group | Phase 3 |
| Completed | Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer NCT00002894 | Medical Research Council | Phase 3 |
| Unknown | Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer NCT00006112 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Completed | Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Pa NCT00002600 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers NCT00002538 | Gynecologic Oncology Group | Phase 2 |
| Withdrawn | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tu NCT00693342 | Gynecologic Oncology Group | Phase 3 |
| Completed | Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary NCT00006235 | Gynecologic Oncology Group | Phase 1 |
| Withdrawn | Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal C NCT00006267 | Gynecologic Oncology Group | Phase 2 |